Efficacy and safety of quinapril in the elderly hypertensive patient.
The efficacy and safety of once-daily administration of the new angiotensin-converting enzyme inhibitor quinapril or quinapril plus hydrochlorothiazide (HCTZ) were assessed in 64 older (greater than 65 years) patients with mild to moderate hypertension in an uncontrolled, open-label study. Treatment was initiated with 20 mg of quinapril once daily and titrated upward to 40 mg of quinapril or 40 mg of quinapril combined with 25 mg of HCTZ according to efficacy. At the end of the 12-week active-treatment phase, 43 patients received 20 mg of quinapril once daily, 12 patients received 40 mg of quinapril once daily, and 4 patients received 40 mg of quinapril combined with 25 mg of HCTZ once daily. Of 48 patients evaluable for efficacy, the mean decrease from baseline in sitting diastolic blood pressure (DBP) was 12.8 mm Hg; 96% of the patients had a blood pressure reduction of greater than or equal to 10 mm Hg, and 98% had a sitting DBP of less than or equal to 90 mm Hg 20 to 28 hours after administration. The decrease in sitting DBP was significant after 1 week and continued for the entire study, as did corresponding changes in sitting systolic blood pressure. We conclude that quinapril administered once daily is well tolerated and effective for the treatment of mild to moderate hypertension in elderly patients.